Cargando…

Measles, mumps, and rubella vaccine at age 6 months and hospitalisation for infection before age 12 months: randomised controlled trial

OBJECTIVE: To test for potential non-specific effects of an additional, early measles, mumps, and rubella (MMR) vaccine at age 5-7 months on risk of infection related hospitalisation before age 12 months. DESIGN: Randomised, double blinded, placebo controlled trial. SETTING: Denmark, a high income s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zimakoff, Anne Cathrine, Jensen, Andreas, Vittrup, Dorthe Maria, Herlufsen, Emma Hoppe, Sørensen, Jesper Kiehn, Malon, Michelle, Svensson, Jannet, Stensballe, Lone Graff
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245144/ https://www.ncbi.nlm.nih.gov/pubmed/37286215 http://dx.doi.org/10.1136/bmj-2022-072724

Ejemplares similares

Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting: study protocol for a randomized controlled trial
por: Vittrup, Dorthe Maria, et al.
Publicado: (2020)

Hair cortisol is not associated with reactogenicity after MMR-vaccination in 6-month-old infants
por: Malon, Michelle, et al.
Publicado: (2023)

Measles–mumps–rubella vaccination and respiratory syncytial virus-associated hospital contact
por: Sørup, Signe, et al.
Publicado: (2015)

Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation
por: Randi, Bruno Azevedo, et al.
Publicado: (2023)

Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6–14 Months During a Measles Outbreak in The Netherlands in 2013–2014
por: van der Maas, Nicoline A. T., et al.
Publicado: (2016)

Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
por: Wang, Zhifang, et al.
Publicado: (2014)

Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age
por: Haas, Hervé, et al.
Publicado: (2019)

Seroconversion rates following 2 doses of measles- mumps- rubella vaccination given at the ages 12 and 18 months: data for possible additional dose at older age
por: Saffar, Hana, et al.
Publicado: (2022)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Is it time to reconsider measles, mumps, and rubella immunisation strategies?
por: Boccalini, Sara, et al.
Publicado: (2021)

Measles-Mumps-Rubella Vaccine and COVID-19 Relationship
por: Özdemir, Öner
Publicado: (2020)

SARS‐CoV‐2 in asymptomatic Danish infants and their mothers from April 2020 to January 2022
por: Malon, Michelle, et al.
Publicado: (2022)

2467. Timeliness of Childhood Vaccination With the Combination Measles–Mumps–Rubella–Varicella Vaccine vs. the Separate Measles–Mumps–Rubella and Varicella Vaccines in the United States
por: Wolfson, Lara, et al.
Publicado: (2018)

Resurgence risk for measles, mumps and rubella in France in 2018 and 2020
por: Béraud, Guillaume, et al.
Publicado: (2018)

Utility of serological screening for measles, mumps and rubella in immunocompromised patients
por: Sticchi, L, et al.
Publicado: (2019)

Inadequate Measles, Mumps, Rubella, and Varicella Immunity Among Employees
por: Ezeji-Okoye, Stephen, et al.
Publicado: (2021)

Knowledge and Practice of Parents Towards Measles, Mumps and Rubella Vaccination
por: Hussein, Siti Zuhaida, et al.
Publicado: (2022)

An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles–Mumps–Rubella (MMR) Vaccination Instead of Current Measles–Rubella (MR) Vaccination
por: Oh, Chunghyeon, et al.
Publicado: (2022)

1339 Measles and Mumps Antibody Response in Young Adults after a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study
Publicado: (2018)

Partial third nerve palsy after Measles Mumps Rubella vaccination
por: Manzotti, Francesca, et al.
Publicado: (2010)

Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart
por: Zamanian, Abbas, et al.
Publicado: (2014)

Perspectives on the Measles, Mumps and Rubella Vaccination among Somali Mothers in Stockholm
por: Jama, Asha, et al.
Publicado: (2018)

Reply to Özdemir, “Measles-Mumps-Rubella Vaccine and COVID-19 Relationship”
por: Fidel, Paul L., et al.
Publicado: (2020)

Measles-mumps-and-rubella-virus-vaccine: Aseptic meningitis: case report
Publicado: (2021)

Measles mumps and rubella virus vaccine: Various toxicities: case report
Publicado: (2022)

Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients
por: Casale, Maddalena, et al.
Publicado: (2021)

Buschke–Lowenstein tumor treated with intralesional measles, mumps, and rubella vaccine
por: Deshmukh, Ashish, et al.
Publicado: (2022)

Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study
por: dos Santos, Eliane Matos, et al.
Publicado: (2019)

Mumps Antibody Response in Young Adults After a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Seroprevalences of Specific IgG Antibodies to Measles, Mumps, and Rubella in Korean Infants
por: Cho, Hye-Kyung, et al.
Publicado: (2016)

Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes
por: Conway, Justin J., et al.
Publicado: (2018)

Comparison of Intralesional Measles, Mumps, Rubella Vaccine and Needling in the Treatment of Recurrent Warts
por: Kolte, Surabhi R., et al.
Publicado: (2020)

Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management
por: Magistà, Stefania, et al.
Publicado: (2020)

1209. Seroprevalence of Measles, Mumps, and Rubella in Korean Healthcare Workers and Strategy for Vaccination
por: Ju Choo, Eun, et al.
Publicado: (2019)

Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients
por: Gold, Jeffrey E., et al.
Publicado: (2020)

A Nationwide Study on the Seroprevalence of Measles, Mumps, and Rubella in Iranian Children and Adolescents
por: Nokhodian, Zary, et al.
Publicado: (2022)

Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink
por: Hanson, Kayla E., et al.
Publicado: (2023)

Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?
por: Salamony, Azza, et al.
Publicado: (2023)

Anticancer Activity of Measles–Mumps–Rubella MMR Vaccine Viruses against Glioblastoma
por: Khalid, Zumama, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2r7hqnothlevuc88rhrhiqv935